At BioAro, we not only pride ourselves with the exceptional service offered to customers, but also  with our unique multidisciplinary approach to genetic and genomic testing. The passion of the  team at BioAro in contributing to and even revolutionizing the field of innovation within biotech, is  another factor that distinguishes BioAro.

The current Canadian genetic and genomic testing market places a greater emphasis on using  pre-established NGS technology and analysis tools to provide often limited reports that focus on  narrowly select genes. BioAro fills a gap in this market by stepping outside of the ordinary and  developing AI based tools such as an NGS based software that allow for personalized medicine  across the disciplines; from pharmacogenomics to oncology.

The longevity of this corporation lies in its great desire in continuous growth, to facilitate the  democratization of access to genomic data through incorporation of blockchain technologies and  cryptocurrencies. BioAro’s platform will be the first Canadian-based of its kind.